What did @steelhealthandhor actually say?
The creator, who appears to represent a clinical TRT practice, made a specific set of claims: anastrozole is their "go to" for symptomatic high estradiol in men on TRT, but it is not a standalone fix. They described a broader management approach that includes adjusting dosing protocols and method of administration. They also flagged an important exception: if someone has high-estradiol symptoms but normal labs, they order a prolactin test and may consider a selective estrogen receptor modulator like raloxifene instead. Finally, they characterized anastrozole as a "non-steroidal, non-suicidal aromatase inhibitor." That last part is a pharmacological classification, not a marketing claim, and it is accurate. The overall framing here is more clinically responsible than most TRT content on TikTok.
Does the science back this up?
Mostly, yes, with some important caveats. Anastrozole does reduce estradiol in hypogonadal men on testosterone therapy, and it is widely used for this purpose. But the evidence base is thinner than the confident tone suggests. The pivotal concern in the literature is over-suppression.
A 2013 study by Burnett-Bowie et al. in the Journal of Bone and Mineral Research found that anastrozole use in older men significantly reduced estradiol and negatively affected bone resorption markers, raising real questions about long-term skeletal safety. Finkelstein et al. (2013, New England Journal of Medicine) showed that estradiol, not just testosterone, plays a significant role in male sexual function and fat distribution. Suppressing it too aggressively can cause exactly the symptoms practitioners are trying to relieve. The creator's note that they "corroborate with blood work" before treating is the clinically appropriate safeguard here. The claim that anastrozole "seems to be extremely well tolerated" is consistent with short-term data but glosses over the bone density and lipid concerns in longer-term use.
What did they get wrong (or right)?
Credit where it is due: the creator got several things right that are routinely botched in TRT content online.
- Treating to symptoms plus labs, not labs alone, reflects current clinical guidance.
- Raising prolactin testing when symptoms and labs do not align is genuinely good clinical thinking. Hyperprolactinemia can mimic high-estradiol symptoms and is often missed.
- Mentioning raloxifene as an alternative for symptom management without lab confirmation shows awareness of receptor-level estrogen dynamics.
What they underplayed: the phrase "we haven't had any issues with it" is anecdotal and potentially misleading to a lay audience watching TikTok. Anastrozole carries documented risks including accelerated bone loss, adverse lipid changes, and joint pain (Leder et al., 2004, Journal of Clinical Endocrinology and Metabolism). Saying risks exist but will be covered "in the head to head comparison" kicks the can down the road for viewers who may not watch that follow-up video.
What should you actually know?
If you are on TRT and your provider is considering anastrozole, there are things worth asking about before you start.
- Has your provider ordered a sensitive estradiol assay, not the standard immunoassay, which is less accurate in men?
- Is bone mineral density monitoring part of the plan for long-term use?
- Has prolactin been checked if your symptoms are not fully explained by estradiol levels?
- Is the dose being adjusted by labs, not just symptoms?
The creator's framing of estrogen management as a multi-variable problem, not a single-drug fix, is the right frame. Estradiol in men is not simply a problem to be eliminated. It is a hormone with legitimate physiological functions. Rashly suppressing it trades one set of symptoms for another. Any provider managing TRT without regular estradiol monitoring, bone density awareness, and a clear titration plan is cutting corners.